StockData
Merck & Co., Inc. logo

Merck & Co., Inc.

MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30242% above fair value
$149.52+3.19 (+2.18%)

Close on Oct 30, 2026Market cap $368.89BP/E 119.6Yield 2.19%

Merck Zepatier (elbasvir and grazoprevir by Quarter

Zepatier (elbasvir and grazoprevir — HCV, legacy) — Worldwide constant-currency (ex-exchange) growth YoY (%) (%)

QuarterlyAnnual

Merck Zepatier (elbasvir and grazoprevir: -32.0% in Q4 2020, up 6.0 pts from a year earlier. No newer figure appears in the documents we track.

Latest, Q4 2020
-32.0%
Period ended Dec 31, 2020
Change on a year earlier
+6.0 pts
-38.0% in Q4 2019
History
13 quarters
Since Q4 2017
Sources
13
Documents cited below

Where the Q4 2020 figure comes from

“|| Zepatier | 55 | 39 | 28 | 45 | 167 | 114 | 108 | 83 | 66 | 370 | -32 | -32 | -55 | -54”

Source: Form 8-K (tm213179d2_ex99-1.htm, filed 2021-02-04) ↗

Reported in Form 8-K Table 3 / 10-K / 10-Q MD&A.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedZepatier (elbasvir and grazoprevir — HCV, legacy) — Worldwide constant-currency (ex-exchange) growth YoY (%) (%)Year on yearSource
Q4 2020Dec 31, 2020-32.0%+6.0 ptsForm 8-K (tm213179d2_ex99-1.htm, filed 2021-02-04) ↗
Q3 2020Sep 30, 2020-67.0%-49.0 ptsForm 8-K (tm2032785d1_ex99-1.htm, filed 2020-10-27) ↗
Q2 2020Jun 30, 2020-62.0%-62.0 ptsForm 8-K (tm2026006d1_ex99-1.htm, filed 2020-07-31) ↗
Q1 2020Mar 31, 2020-51.0%-42.0 ptsForm 8-K (tm2016917d1_ex99-1.htm, filed 2020-04-28) ↗
Q4 2019Dec 31, 2019-38.0%+24.0 ptsForm 8-K (tm206551d1_ex99-1.htm, filed 2020-02-05) ↗
Q3 2019Sep 30, 2019-18.0%+59.0 ptsForm 8-K (tm1921023d1_ex99-1.htm, filed 2019-10-29) ↗
Q2 2019Jun 30, 20190.0%+80.0 ptsForm 8-K (a19-15283_1ex99d1.htm, filed 2019-07-30) ↗
Q1 2019Mar 31, 2019-9.0%+60.0 ptsForm 8-K (a19-8996_1ex99d1.htm, filed 2019-04-30) ↗
Q4 2018Dec 31, 2018-62.0%-89.0 ptsForm 8-K (a19-3795_1ex99d1.htm, filed 2019-02-01) ↗
Q3 2018Sep 30, 2018-77.0%–Form 8-K (a18-37128_1ex99d1.htm, filed 2018-10-25) ↗
Q2 2018Jun 30, 2018-80.0%–Form 8-K (a18-17779_1ex99d1.htm, filed 2018-07-27) ↗
Q1 2018Mar 31, 2018-69.0%–Form 8-K (a18-12417_1ex99d1.htm, filed 2018-05-01) ↗
Q4 2017Dec 31, 201727.0%–Form 8-K (a18-5152_1ex99d1.htm, filed 2018-02-02) ↗

Cite this data

StockData. (2026). Merck Zepatier (elbasvir and grazoprevir (%), quarterly Q4 2017–Q4 2020 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev-zepatier-ww-exfx-yoy

See every metric in the Merck KPI table. Data updated Oct 26, 2026.